EGFR and adenocarcinoma: Remarkably, a total of 135 (9.3%) non‐adenocarcinoma tumors harbored EGFR mutations, including 10 with squamous cell carcinoma, two with mixed histology, and 123 with carcinoma not otherwise specified, that were tested given the clinical indication.